Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Methotrexate | HCID 126941 | — |
| Reactant | 1,1-Dihydroxypropan-2-one | HCID 13180982 | — |
| Reactant | 2,4,5,6-Tetraaminopyrimidine hydrochloride | HCID 20477346 | — |
| Solvent | Water | HCID 962 | — |
| Product | HCID 178432404 | HCID 178432404 | — |
Reaction Steps
The well-known Ellard process is exemplified by U.S. Pat. No. 4,080,325 Ellard and claim 1 of the patent sets out the steps for preparing methotrexate as follows: (a) reacting tetraaminopyrimidinehydrochloride with dihydroxyacetone in the presence of air and water and at a pH in the range of 5.5±0.2 to give 2,4-diamino-6-hydroxy-methylpteridine; (b) converting the 2,4-diamino-6-hydroxy-methylpteridine to the hydrobromide salt, namely, 2,4-diamino-6-hydroxymethylpteridine hydrobromide salt; (c) reacting the 2,4-diamino-6-hydroxymethylpteridine hydrobromide salt with triphenyldibromophosphorane to give 2,4-bis(triphenylphosphazine)-6-bromomethylpteridine hydrobromide; (d) reacting the 2,4-bis(triphenylphosphazino)-6-bromomethylpteridine hydrobromide with ethyl N-(p-methylamino)benzylglutamate to give the phosphazino derivative of methotrexate ester; (e) hydrolyzing the phosphazino derivative of methotrexate ester to give triphenylphosphine oxide and methotrexate ester; and (f) hydrolyzing the methotrexate ester to give methotrexate.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US04421913 |
|---|
| Source dataset | uspto-grants-1983_12 |
|---|
| ORD ID | ord-a2a198a517b241ec97f299a38a94d584 |
|---|
| Source note | uspto-grants-1983_12 |
|---|